Mayne Pharma Sustainability Profile
Mayne Pharma Group Limited, commonly referred to as Mayne Pharma, is a prominent Australian pharmaceutical company headquartered in Adelaide, South Australia. Founded in 1850, the company has established itself as a key player in the global pharmaceutical industry, focusing on the development and manufacturing of generic and specialty pharmaceuticals. With a strong presence in both the Australian and international markets, Mayne Pharma is renowned for its innovative drug delivery systems and high-quality generic medications. The company’s core offerings include a diverse range of oral and topical formulations, particularly in the areas of oncology, dermatology, and women's health. Mayne Pharma has achieved significant milestones, including strategic acquisitions and partnerships that have bolstered its market position. Its commitment to quality and innovation has earned it a reputation for excellence, making it a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Mayne Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mayne Pharma's score of 16 is lower than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mayne Pharma's reported carbon emissions
Mayne Pharma, headquartered in Australia, has reported its carbon emissions data for the years 2015 and 2016. In 2016, the company had a GHG emissions intensity of approximately 0.0696 kg CO2e per AUD of revenue, while in 2015, this figure was about 0.0955 kg CO2e per AUD of revenue. However, specific absolute emissions figures for Scope 1, 2, and 3 are not disclosed, indicating a lack of detailed emissions reporting. Currently, Mayne Pharma does not have any publicly stated reduction targets or commitments under the Science Based Targets initiative (SBTi) or other climate pledges. The absence of such targets suggests that the company may be in the early stages of developing a comprehensive climate strategy. As of now, there is no cascaded emissions data from a parent or related organization, indicating that all reported information is directly from Mayne Pharma Group Limited. The company is encouraged to enhance its emissions reporting and set measurable reduction targets to align with industry standards and climate commitments.
How Carbon Intensive is Mayne Pharma's Industry?
How Carbon Intensive is Mayne Pharma's Location?
Mayne Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Mayne Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
